Behavioral Outcome Measures for the Assessment of Sensorimotor Function in Animal Models of Movement Disorders

International Review of Neurobiology

Volumn 89, Issue C, 2009, Pages 57-65

  Fleming, Sheila M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Challenging beam traversal; Limb use asymmetry; Mice; Parkinson's disease; Rats

Indexed keywords

OXIDOPAMINE;

ANIMAL BEHAVIOR; BODY EQUILIBRIUM; DISEASE MODEL; EXPLORATORY BEHAVIOR; GENE MUTATION; KNOCKOUT MOUSE; LIMB MOVEMENT; MOTOR DYSFUNCTION; NESTING; NEUROLOGIC EXAMINATION; NEWBORN MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; SENSORIMOTOR FUNCTION; SENSORY STIMULATION; STIMULUS RESPONSE; THERMOREGULATION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; FUNCTIONAL LATERALITY; HYDROXYDOPAMINES; MICE; MOTOR ACTIVITY; MOVEMENT DISORDERS; NESTING BEHAVIOR; PARKINSON DISEASE, SECONDARY; PSYCHOMOTOR PERFORMANCE; RATS;

EID: 71749099185     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)89003-X     Document Type: Review

References (50)

1. Broida J., and Svare B. Strain-typical patterns of pregnancy-induced nestbuilding in mice: Maternal and experiential influences. Physiol. Behav. 29 1 (1982) 53-57
2. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience 88 2 (1999) 617-628
3. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
4. Chen L., Cagniard B., Matthews T., Jones S., Koh H.C., Ding Y., Carvey P.M., Ling Z., Kang U.J., and Zhuang X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem. 280 22 (2005) 21418-21426
5. Cohen G., and Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249 8 (1974) 2447-2452
6. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., and Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6 12 (1999) 1936-1951
7. Crawley J.N. What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice (2000), Wiley-Liss, New York
8. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.-F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
9. Fleming S.M., Zhu C., Fernagut P.-O., Mehta A., DiCarlo C.D., Seaman R.L., and Chesselet M.-F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 187 (2004) 418-429
10. Fleming S.M., Delville Y., and Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: Antiparkinson effects of sinemet and protective effects of methylphenidate. Behav. Brain Res. 156 2 (2005) 201-213
11. Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.-F. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 142 4 (2006) 1245-1253
12. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 (2003) 43628-43635
13. Heikkila R., and Cohen G. Inhibition of biogenic amine uptake by hydrogen peroxide: A mechanism for toxic effects of 6-hydroxydopamine. Science 172 989 (1971) 1257-1258
14. Heikkila R., and Cohen G. 6-Hydroxydopamine: Evidence for superoxide radical as an oxidative intermediate. Science 181 98 (1973) 456-457
15. Hofele K., Sedelis M., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Exp. Neurol. 168 1 (2001) 116-122
16. Hwang D.Y., Ardayfio P., Kang U.J., Semina E.V., and Kim K.S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114 2 (2003) 123-131
17. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.-F., and Kim K.S. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: Behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25 8 (2005) 2132-2137
18. Kostrzewa R.M., and Jacobwitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26 3 (1974) 199-288
19. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., and Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 166 1 (2000) 1-15
20. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schöls L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
21. LeVere T.E. Neural system imbalances and the consequences of large brain injuries. In: Finger S., LeVere T.E., Almi C.R., and Stein D.G. (Eds). Brain Injury and Recovery, Theoretical and Controversial Issues (1988), Plenum Press, New York 1-362
22. Lindner M.D., Winn S.R., Baetge E.E., Hammang J.P., Gentile F.T., Doherty E., McDermott P.E., Frydel B., Ullman M.D., Schallert T., and Emerich D.F. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. 132 1 (1996) 62-76
23. Lu X.H., Fleming S.M., Meurers B., Mortazavi F., Lo V., Hernandez D., Sulzer D., Jackson G.R., Maidment N.T., Chesselet M.-F., and Yang X.W. BAC mice expressing a truncated mutant parkin exhibit progressive motor deficits and late-onset dopaminergic neuron degeneration. J. Neurosci. 29 7 (2009) 1962-1976
24. Luo J., Kaplitt M.G., Fitzsimons H.L., Zuzga D.S., Liu Y., Oshinsky M.L., and During M.J. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 5592 (2002) 425-429
25. Lynch C.B. Response to divergent selection for nesting behavior in Mus musculus. Genetics 96 3 (1980) 757-765
26. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15 5 Pt 2 (1995) 3863-3875
27. Page L.J., Suk J.-Y., Bazhenova L., Fleming S.M., Wood M., Jiang Y., Guo L.T., Misizin A.P., Kisilevsky R., Shelton G.D., Kelly J.W., and Balch W.E. A gelsolin amyloidosis mouse exhibiting an age-associated decline in proteostasis triggers sporadic inclusion body myositis (sIBM). PNAS. 106 27 (2009) 11125-11130
28. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
29. Reliene R., Fleming S.M., Chesselet M.-F., and Schiestl R.H. Effects of antioxidants on cancer prevention and neuromotor deficits in ATM deficient mice. Food Chem. Toxicol. 46 (2008) 1371-1377
30. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C.W., Lang I., and Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68 (2002) 568-578
31. Schallert T., and Hall S. 'Disengage' sensorimotor deficit following apparent recovery from unilateral dopamine depletion. Behav. Brain Res. 30 (1988) 15-24
32. Schallert T., and Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism: Optimizing behavioral assessment of outcome. In: Emerich D.F., Dean III R.L., and Sandberg P.R. (Eds). Central Nervous System Diseases (2000), Humana Press, Totowa, NJ
33. Schallert T., and Wilcox R.E. Neurotransmitter-selective brain lesions. In: Boulton A.A., and Baker G.B. (Eds). Neuromethods (Series 1: Neurochemistry), General Neurochemical Techniques (1985), Humana Press, Totowa, NJ 343-387
34. Schallert T., Whishaw I.Q., Ramirez V.D., and Teitelbaum P. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science 199 (1978) 1461-1463
35. Schallert T., Upchurch M., Lobaugh N., Farrar S.B., Spirduso W.W., Gilliam P., Vaughn D., and Wilcox R.E. Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol. Biochem. Behav. 16 3 (1982) 455-462
36. Schallert T., Upchurch M., Wilcox R.E., and Vaughn D.M. Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum. Pharmacol. Biochem. Behav. 18 5 (1983) 753-759
37. Schallert T., Norton D., and Jones T.A. A clinically relevant unilateral rat model of parkinsonian akinesia. J. Neural. Trans. Plasticity 3 (1992) 332-333
38. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 5 (2000) 777-787
39. Schallert T., Woodlee M.T., and Fleming S.M. Disentangling multiple types of recovery from brain injury. In: Krieglstein J., and Klumpp S. (Eds). Pharmacology of Cerebral Ischemia (2002), Medpharm Scientific Publishers, Stuttgart, Germany 201-216
40. Sedelis M., Schwarting R.K., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
41. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
42. Szczypka M.S., Kwok K., Brot M.D., Marck B.T., Matsumoto A.M., Donahue B.A., and Palmiter R.D. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30 3 (2001) 819-828
43. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21 12 (2001) 4427-4435
44. Tillerson J.L., Cohen A.D., Caudle W.M., Zigmond M.J., Schallert T., and Miller G.W. Forced nonuse in unilateral parkinsonian rats exacerbates injury. J. Neurosci. 22 15 (2002) 6790-6799
45. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1 methyl-4-phenyl 1,2,3,6-tetrahydropyridine. Exp. Neurol. 178 (2002) 80-90
46. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 1 (1968) 107-110
47. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Act. Physiol. Scand. Suppl. 367 (1971) 95-122
48. Upchurch M., and Schallert T. A behavior analysis of the offspring of "haloperidol-sensitive" and "haloperidol-resistant" gerbils. Behav. Neural. Biol. 39 2 (1983) 221-228
49. Whishaw I.Q. Loss of the innate cortical engram for action patterns used in skilled reaching and the development of behavioral compensation following motor cortex lesions in the rat. Neuropharmacology 39 5 (2000) 788-805
50. Yang M., Stull N.D., Berk M.A., Snyder E.Y., and Iacovitti L. Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp. Neurol. 177 1 (2002) 50-60